{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:35:35Z","timestamp":1778880935037,"version":"3.51.4"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>When treating Beh\u00e7et\u2019s disease (BD), anti-tumor necrosis factor (TNF)-\u03b1 agents have become a second-line therapy when conventional immunosuppressive drugs have failed. However, in the case of failure of treatment with anti-TNF\u03b1 drugs, further options are limited. Based on previous reports of the efficacy of vedolizumab (VDZ) in inflammatory bowel diseases, we decided to administer VDZ to treat a patient with intestinal BD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We present the case of a 49-year-old female patient with BD. Her clinical manifestations included erythema nodosum, oro-genital ulcers, positive Pathergy test, positive HLA-B51, and biopsy-proven intestinal BD. The patient was unsuccessfully treated with conventional immunosuppressive and several biological agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment with VDZ was started intravenously at a dose of 300 mg at 0, 2, and 6 weeks and then every 4 weeks.<\/jats:p><jats:p>After the second dose of VDZ, the patient reported a marked improvement of intestinal BD and a concomitant amelioration of arthralgia, erythema nodosum lesions and aphthosis. Clinical remission was achieved at 6 months after starting VDZ.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>VDZ might represent a valid option to treat patients with BD who are non-responsive to standard treatments or anti-TNF\u03b1 agents, particularly, those cases with intestinal involvement.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.769785","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T06:38:25Z","timestamp":1635143905000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Vedolizumab for the Management of Refractory\u00a0Beh\u00e7et\u2019s Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Marta","family":"Arbrile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Radin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Menegatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Baldovino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2019.01.001","article-title":"Beh\u00e7et Syndrome: A Great Imitator","volume":"37","author":"Akdeniz","year":"2019","journal-title":"Clin Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24642","article-title":"HLA-B51\/B5 and the Risk of Beh\u00e7et\u2019s Disease: A Systematic Review and Meta-Analysis of Case-Control Genetic Association Studies","volume":"61","author":"De Menthon","year":"2009","journal-title":"Arthritis Care Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01067","article-title":"Beh\u00e7et\u2019s Disease: An Overview of Etiopathogenesis","volume":"10","author":"Leccese","year":"2019","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-019-02035-1","article-title":"Update on the Treatment of Beh\u00e7et\u2019s Syndrome","volume":"14","author":"Esatoglu","year":"2019","journal-title":"Intern Emerg Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.624795","article-title":"Treatment of Beh\u00e7et\u2019s Disease: An Algorithmic Multidisciplinary Approach","volume":"8","author":"Alpsoy","year":"2021","journal-title":"Front Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"107421","DOI":"10.1155\/2014\/107421","article-title":"Biological Treatments in Beh\u00e7et\u2019s Disease: Beyond Anti-TNF Therapy","volume":"2014","author":"Caso","year":"2014","journal-title":"Mediators Inflamm"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as Induction and Maintenance Therapy for Crohn\u2019s Disease: Commentary","volume":"14","author":"Balzola","year":"2014","journal-title":"Inflammation Bowel Dis Monit"},{"key":"B8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/nejmoa1215734","article-title":"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J Crohn\u2019s Colitis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2007.22.5.918","article-title":"A Case of Intestinal Behcet\u2019s Disease Similar to Crohn\u2019s Colitis","volume":"22","author":"Kim","year":"2007","journal-title":"J Korean Med Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3904\/KJIM.2015.30.5.714","article-title":"Cross-Cultural Adaptation and Validation of the Behcet\u2019s Disease Current Activity Form in Korea","volume":"30","author":"C","year":"2015","journal-title":"Korean J Intern Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): A Collaborative Study of 27 Countries on the Sensitivity and Specificity of the New Criteria","volume":"28","author":"Davatchi","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200003000-00006","article-title":"Gastrointestinal Manifestations of Behcet\u2019s Disease","volume":"30","author":"Bayraktar","year":"2000","journal-title":"J Clin Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","article-title":"Effectiveness of Tocilizumab in Behcet\u2019s Disease: A Systematic Literature Review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheumatol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.55563\/clinexprheumatol\/9ipkcs","article-title":"Tocilizumab in Beh\u00e7et\u2019s Disease With Refractory Ocular and\/or Neurological Involvement: Response According to Different Clinical Phenotypes","volume":"132","author":"Atienza-Mateo","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease","volume":"63","author":"Fleisher","year":"2018","journal-title":"Dig Dis Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01460-3","article-title":"Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease","volume":"81","author":"Hanzel","year":"2021","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.11.008","article-title":"Leukocyte Integrins: Role in Leukocyte Recruitment and as Therapeutic Targets in Inflammatory Disease","volume":"147","author":"Mitroulis","year":"2015","journal-title":"Pharmacol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.769785\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T16:45:01Z","timestamp":1673628301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.769785\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2021.769785"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.769785","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"article-number":"769785"}}